Latest Financial Strategy News

Stanmore Resources reports a challenging first half of 2025 with lower coal prices and significant wet weather impacting production and earnings, but maintains safety excellence and cost discipline while preparing for a second-half recovery and growth projects.

Entertainment Rewards Ltd has expanded its loan facility by $3 million with Suzerain Investment Holdings, aiming to accelerate its Revenue Pivot Strategy and strengthen working capital.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Cannindah Resources Limited has voluntarily suspended its shares from trading as it prepares to announce a significant capital raising. The suspension is set to last until the announcement or the resumption of trading on August 22.

Super Retail Group has announced it will suspend its Dividend Reinvestment Plan starting fiscal year 2026, shifting shareholders to cash dividends instead. The DRP remains active for FY25 final and special dividends.

Vital Metals Limited has voluntarily suspended trading of its shares pending a key announcement on a capital raise, following an ASX price and volume query.

Wingara AG Limited has officially terminated its planned placement and loan agreement with Terra Firma Equity Limited, leaving its capital raising strategy uncertain.

Lake Resources N.L. has had its trading suspension lifted following the release of a capital raising announcement, signaling renewed market activity for the lithium explorer.

Universal Biosensors has extended the due diligence period with major investor Viburnum Funds as it continues to negotiate a secured loan facility, with no binding commitment yet reached.

Metal Bank Limited has announced its withdrawal from exploration activities in Jordan, citing geopolitical instability and financial guarantees demanded by local authorities as key reasons.

The Star Entertainment Group has executed binding agreements to exit its 50% stake in the Destination Brisbane Consortium, while consolidating full ownership of key Gold Coast hotels. The transaction unfolds in two stages, reshaping the company’s asset portfolio and financial commitments.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.